skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Safety and outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathy

Schubart, Jane R ; Zare, Amirhossein ; Fernandez-de-Castro, Roberto M ; Figueroa, Hector Rosario ; Sarel, Ina ; Tuchman, Kelly ; Esposito, Kaitlyn ; Henderson, Fraser C ; von Schwarz, Ernst

Stem cell research & therapy, 2023-10, Vol.14 (1), p.1-308, Article 308 [Periódico revisado por pares]

London: BioMed Central Ltd

Texto completo disponível

Citações Citado por
  • Título:
    Safety and outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathy
  • Autor: Schubart, Jane R ; Zare, Amirhossein ; Fernandez-de-Castro, Roberto M ; Figueroa, Hector Rosario ; Sarel, Ina ; Tuchman, Kelly ; Esposito, Kaitlyn ; Henderson, Fraser C ; von Schwarz, Ernst
  • Assuntos: Analysis ; Angina pectoris ; Angiogenesis ; Angiogenin ; Anti-apoptosis ; Apoptosis ; Autografts ; Autologous hematopoietic stem cell ; Blood vessels ; Bone marrow ; Cardiomyocytes ; Cardiomyopathy ; Care and treatment ; Catheters ; CD34 antigen ; Cell number ; Cytokine IL-8 ; Data collection ; Dilated cardiomyopathy ; Echocardiography ; Ejection fraction ; Endothelial growth factors ; Flow cytometry ; Heart ; Heart diseases ; Heart failure ; Hospitalization ; Hypothesis testing ; Ischemia ; NF-kB ; Patient outcomes ; Patients ; Progenitor cells ; Quality of life ; Respiratory tract infection ; Stem cell transplantation ; Stem cells ; Tachycardia ; Transplantation ; Transplants & implants ; Ultrasonic imaging ; Vascular endothelial growth factor ; VEGF ; Ventricle
  • É parte de: Stem cell research & therapy, 2023-10, Vol.14 (1), p.1-308, Article 308
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Background Stem cell transplantation is an emerging therapy for severe cardiomyopathy, proffering stem cell recruitment, anti-apoptosis, and proangiogenic capabilities. Angiogenic cell precursors (ACP-01) are autologous, lineage-specific, cells derived from a multipotent progenitor cell population, with strong potential to effectively engraft, form blood vessels, and support tissue survival and regeneration. Methods This IRB approved outcome analysis reports upon 74 consecutive patients who failed medical management for severe cardiomyopathy, and were selected to undergo transcatheter intramyocardial or intracoronary implantation of ACP-01. Serious adverse events (SAEs) were reported. Cell analysis was conducted for each treatment. The left ventricular ejection fraction (LVEF) was measured by multi-gated acquisition scan (MUGA) or echocardiogram at 4 months [+ or -] 1.9 months and 12 months [+ or -] 5.5 months. Patients reported quality of life statements at 6 months ([+ or -] 5.6 months). Results Fifty-four of 74 patients met requirements for inclusion (48 males and five females; age 68.1 [+ or -] 11.3 years). The mean treatment cell number of 57 x 10.sup.6 ACP-01 included 7.7 x 10.sup.6 CD34 + and 21 x 10.sup.6 CD31 + cells with 97.6% viability. SAEs included one death (previously unrecognized silent MI), ventricular tachycardia (n = 2) requiring cardioversion, and respiratory infection (n = 2). LVEF in the ischemic subgroup (n = 41) improved by 4.7% [+ or -] 9.7 from pre-procedure to the first follow-up (4 months [+ or -] 1.9 months) (p < 0.004) and by 7.2% [+ or -] 10.9 at final follow-up (n = 25) at average 12 months (p < 0.004). The non-ischemic dilated cardiomyopathy subgroup (n = 8) improved by 7.5% [+ or -] 6.0 at the first follow-up (p < 0.017) and by 12.2% [+ or -] 6.4 at final follow-up (p < 0.003, n = 6). Overall improvement in LVEF from pre-procedure to post-procedure was significant (Fisher's exact test p < 0.004). LVEF improvement was most marked in the patients with the most severe cardiomyopathy (LVEF < 20%) improving from a mean 14.6% [+ or -] 3.4% pre-procedurally to 28.4% [+ or -] 8% at final follow-up. Quality of life statements reflected improvement in 33/50 (66%), no change in 14/50 (28%), and worse in 3/50 (6%). Conclusion Transcatheter implantation of ACP-01 for cardiomyopathy is safe and improves LVEF in the setting of ischemic and non-ischemic cardiomyopathy. The results warrant further investigation in a prospective, blinded, and controlled clinical study. Trial Registration: IRB from Genetic Alliance #APC01-001, approval date July 25, 2022. Condensed Cardiomyopathy is common and associated with high mortality. Stem cell transplantation is an emerging therapy. Angiogenic cell precursors (ACP-01) are lineage-specific endothelial progenitors, with strong potential for migration, engraftment, angiogenesis, and support of tissue survival and regeneration. A retrospective outcomes analysis of 53 patients with ischemic and non-ischemic dilated cardiomyopathy undergoing transcatheter implantation of ACP-01 demonstrated improvements in the left ventricular ejection fraction of 7.2% [+ or -] 10.9 (p < 0.004) and 12.2% [+ or -] 6.4, respectively, at 12 months ([+ or -] 5) follow-up. Quality of life statements reflected improvement in 33/50 (66%) patients. Keywords: Autologous hematopoietic stem cell, VEGF, Angiogenin, Cytokine IL-8, NF-kB, Anti-apoptosis, Cardiomyopathy, Angiogenic stem cell, Angiogenesis
  • Editor: London: BioMed Central Ltd
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.